| Date | Title | | | | 12/2/2014 | Meridian Life Science Awarded SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine| CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2014--
Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned
subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to
announce they have been selected by the Centers for Disease Control and
Prevention (CDC) to develop a process for manufacture of a rotavirus
vaccine. Funding for this activity will be provided through a Small
Business Innovation Research (SBIR) contract. Process development... |
| |  | | 11/6/2014 | Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 6, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported fourth quarter and full-year fiscal 2014 net revenues of
$46.7 million and $188.8 million, respectively, a decrease of 5% and
an increase of less than 1%, respectively, from the same periods of
the prior fiscal year;
reporte... |
| | | | 9/3/2014 | Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae| CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2014--
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced
it has signed a new agreement with Premier, Inc. to offer the complete illumigene®
molecular menu of tests to its members. Premier serves more
than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This
agreement offers each Premier healthcare facility the opportunity to
implement rapid, sensitive, molecular tests for C. diffic... |
| | | | 9/2/2014 | Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance| CINCINNATI--(BUSINESS WIRE)--Sep. 2, 2014--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
provided the financial community with guidance regarding the Company’s
fiscal 2015 sales and earnings estimates. Based on the Company’s
business planning and budgeting activities for the fiscal year ending
September 30, 2015, management expects net revenues to be in the range
of $193 to $200 million, or 2% to 5% growth, and per share diluted
... |
| | | | 8/6/2014 | Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology| CINCINNATI--(BUSINESS WIRE)--Aug. 6, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has
entered into a technology and commercial license agreement with the
University of Tennessee Research Foundation (UTRF) for the development
of an innovative new technology that has the potential to result in a
low cost, point-of-care detection platform capable of detecting
proteins, small molecules, bacteria and viruses in minutes.
... |
| | | | 7/24/2014 | Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance| CINCINNATI--(BUSINESS WIRE)--Jul. 24, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported fiscal 2014 third quarter and first nine months net sales of
$47.2 million and $142.1 million, respectively, flat and an increase
of 2%, respectively, from the same periods of the prior fiscal year;
reported third quarter operating income of $13.1 million, a decrease
of 16% from the same period of the prior fisca... |
| | | | 5/28/2014 | Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene® Pertussis| CINCINNATI--(BUSINESS WIRE)--May 28, 2014--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has received medical device license approval from
Health Canada to market two additional assays for use on their illumigene®
molecular diagnostic platform. With the addition of illumigene
Mycoplasma and illumigene Pertussis, Meridian continues to
expand its position in the Canadian market by providing innovative
testing so... |
| | | | 4/24/2014 | Meridian Bioscience Reports Second Quarter 2014 Operating Results and Revises Fiscal 2014 Guidance| CINCINNATI--(BUSINESS WIRE)--Apr. 24, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported record fiscal 2014 second quarter and first six months net
sales of $50.1 million and $94.9 million, respectively, increases of
6% and 2%, respectively, from the same periods of the prior fiscal
year;
reported second quarte... |
| | | | 3/27/2014 | Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Pertussis| CINCINNATI--(BUSINESS WIRE)--Mar. 27, 2014--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has received FDA clearance for a new molecular
diagnostic test for Bordetella pertussis (B. pertussis),
its fifth assay on the illumigene platform. This
innovative test is the first FDA-cleared molecular stand-alone assay for B.
pertussis providing a solution to the unmet need of today’s
healthcare market.
... |
| | | | 2/18/2014 | Bioline Launches New Products for Epigenetics Research| CINCINNATI--(BUSINESS WIRE)--Feb. 18, 2014--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the
rapidly growing Epigenetics field, with the launch of the first kits in
the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™
Amplification Kit.
These EPIKTM Kits have been developed to meet the needs of
researchers employing PCR and real-time PCR analy... |
| | | | 2/7/2014 | Bioline Launches High Performance SensiFAST™ cDNA Synthesis Kit| CINCINNATI--(BUSINESS WIRE)--Feb. 7, 2014--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of the SensiFASTTM cDNA synthesis kit. Powered by a
newly developed Reverse Transcriptase enzyme with enhanced properties
and in combination with the unique TransAmp™ buffer; SensiFASTTM
cDNA synthesis kit is the choice for scientists who need consistent,
unbiased, fi... |
| | | | 1/22/2014 | Meridian Bioscience Reports First Quarter 2014 Operating Results, Declares Increased Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported first quarter net sales of $44.8 million, a decrease of 1%
from the same period of the prior fiscal year;
reported first quarter operating income of $11.6 million, a decrease
of 11% from the same period of the prior fiscal year;
reported first quarter net earnings of $7.4 million, or $0.18 per
... |
| | | | 1/15/2014 | Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business| CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than
expected preliminary operating results for the first quarter ended
December 31, 2013.
Fiscal 2014 First Quarter Preliminary Outlook
Due to factors including reduced hospital admissions and declining C.
difficile incidence rates in hospitals putting further pressure on
an already competitive market, Life Science shipment... |
| | | | 1/14/2014 | Bioline Expands into Singapore| CINCINNATI--(BUSINESS WIRE)--Jan. 14, 2014--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an
office in Singapore to support and grow the Bioline business in
Singapore and in Asia.
With the opening of the new office; Bioline will provide direct sales,
technical support, and training to its existing customers and can also
offer a same-day delivery to many ... |
| | | | 1/10/2014 | Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU® to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim| CINCINNATI--(BUSINESS WIRE)--Jan. 10, 2014--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the
company’s TRU FLU® assay received FDA clearance for an
analytical sensitivity claim for the novel avian Influenza H7N9 strain,
A/Anhui/1/2013. TRU FLU® is a rapid immunoassay that detects
influenza A and influenza B viruses in 15 minutes in human respiratory
specimens.
New strains of Influenza viruses are continuously emerging to ... |
| | |
|
